High urgency

August 29, 2022: FDA warns “Tramadol US” to stop selling controlled, unapproved drugs to U.S. residents - Partnership for Safe Medicines

Detected September 2, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA warns 'Tramadol US' to cease selling controlled, unapproved drugs to U.S. residents.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers and distributors involved in the sale of controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate cessation required upon receipt of the warning.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

The FDA has issued a warning to stop the sale of controlled, unapproved drugs to U.S. residents.

Who it affects

All pharmaceutical manufacturers and distributors involved in the sale of controlled substances.

What you must do

Immediately halt the sale of any controlled substances that are not FDA-approved.

Deadline

Immediate cessation required upon receipt of the warning.

Source: https://news.google.com/rss/articles/CBMiaEFVX3lxTFBYVmZnekJCQ2hxTDNzSGVabC1HUHUxNFpRWnlPeW9JV0Rxb255UUwxSjZxR1dRYy1ZVkFZZnA3bV9ldVVXT1VkLTZlY1BBMzVCS0xlbTAzT3N5ODRUVm9pV1Juby1oalBv?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)